Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis

被引：2
|
作者：
Medina-De la Garza, Carlos Eduardo [1 ,2 ]
Flores-Torres, Armando Salvador [1 ]
Garcia-Hernandez, Marisela [1 ,3 ,4 ]
de los Angeles Castro-Corona, Maria [1 ,2 ]
机构：
[1] Univ Autonoma Nuevo Leon, Immunomodulat Unit, Ctr Res & Dev Hlth Sci CIDICS, Monterrey, Mexico
[2] Univ Autonoma Nuevo Leon, Serv Immunol, Av Gonzalitos 235,Mitras Ctr, Monterrey 64460, Mexico
[3] Univ Autonoma Nuevo Leon, Biochem & Mol Med Dept, Sch Med, Monterrey, Mexico
[4] Univ Autonoma Nuevo Leon, Univ Hosp Dr Jose E Gonzalez, Av Gonzalitos 235,Mitras Ctr, Monterrey 64460, Mexico
来源：
MEDICAL HYPOTHESES | 2022年 / 160卷
关键词：
Diethylcarbamazine; Drug repurposing; Pulmonary fibrosis; COVID-19-related pulmonary fibrosis; Post-COVID-19;
D O I：
10.1016/j.mehy.2022.110774
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies should assess this possible effect.
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Lung Fibrosis after COVID-19: Treatment Prospects
    Bazdyrev, Evgeny
    Rusina, Polina
    Panova, Maria
    Novikov, Fedor
    Grishagin, Ivan
    Nebolsin, Vladimir
    PHARMACEUTICALS, 2021, 14 (08)
  • [2] Potential mechanisms for lung fibrosis associated with COVID-19 infection
    Parimon, T.
    Espindola, M.
    Marchevsky, A.
    Rampolla, R.
    Chen, P.
    Hogaboam, C. M.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2023, 116 (07) : 487 - 492
  • [3] COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts
    John, Alison E.
    Joseph, Chitra
    Jenkins, Gisli
    Tatler, Amanda L.
    IMMUNOLOGICAL REVIEWS, 2021, 302 (01) : 228 - 240
  • [4] Some aspects of lung fibrosis in COVID-19
    Zinserling, V.
    Semenova, N.
    Baram, D.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S24 - S24
  • [5] Potential treatment of COVID-19
    Ayten, Omer
    Ozdemir, Cengiz
    Akturk, Ulku Aka
    Sen, Nazan
    EURASIAN JOURNAL OF PULMONOLOGY, 2020, 22 (04) : 35 - 44
  • [6] Low dose lung radiotherapy for COVID-19 pneumonia: A potential treatment
    Gupta, Sweety
    Ahuja, Rachit
    Sharma, Nidhi
    Singh, Pragya
    Verma, Swati
    Gupta, Manoj
    RESPIRATORY MEDICINE, 2021, 186
  • [7] Interstitial Lung Fibrosis Following COVID-19 Pneumonia
    Lazar, Mihai
    Barbu, Ecaterina Constanta
    Chitu, Cristina Emilia
    Tiliscan, Catalin
    Stratan, Laurentiu
    Arama, Sorin Stefan
    Arama, Victoria
    Ion, Daniela Adriana
    DIAGNOSTICS, 2022, 12 (08)
  • [8] Montelukast as a potential treatment for COVID-19
    McCarthy, Matthew. W. W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (05) : 551 - 555
  • [9] Simnotrelvir as a potential treatment for COVID-19
    McCarthy, Matthew W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (03) : 233 - 237
  • [10] As a potential treatment of COVID-19: Montelukast
    Fidan, Cihan
    Aydogdu, Ayse
    MEDICAL HYPOTHESES, 2020, 142
12345